Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

JFais Jul. 14 at 5:19 PM

$SNDX - as if $INCY needed more reasons to bolster its heme franchise

0 · Reply

2_logs_higher Jul. 14 at 1:12 PM

$INCY PT $140 https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-incyte-stock-rating-on-vwd-drug-data-93CH-4790640

0 · Reply

2_logs_higher Jul. 13 at 12:09 PM

$INCY https://finance.yahoo.com/healthcare/articles/incyte-presents-phase-1-2-080000581.html

0 · Reply

AdamBrennan2 Jul. 9 at 2:39 AM

$INCY even thought the stock is doing very well; look at the amount of Free Cash Flow and Net Income decline this stock is pricing in at current market cap / enterprise value levels $BBIO $ARGX $ABBV $AMGN

0 · Reply

JFais Jul. 8 at 2:18 PM

$SNDX (L @ $9.23, 9% PW) Curling up nicely ahead of data readouts for IPF and 1L GVHD (Jakafi combo) for Niktimvo later this year $INCY

0 · Reply

AXLFI_HQ Jul. 6 at 11:10 PM

$INCY Healthcare companies are pursuing strategic acquisitions and partnerships to consolidate complementary capabilities, expand addressable markets, and achieve faster market access through integrated platforms. Learn more: https://axlfi.com/themes/379

0 · Reply

2_logs_higher Jul. 6 at 6:35 PM

$INCY another victory for INCY. Now we just need INCY to take out $AGEN https://www.thepharmaletter.com/biotech-news/mhra-approves-retifanlimab-for-rare-skin-cancer

1 · Reply

Alpha_Ascendant Jul. 4 at 11:29 AM

$MIRM Up 188% since my first report, this biotech is performing, building a liver disease franchise with a clutch of approved drugs while promising pipeline candidates --Volixibat, MRM-3379, Brelovitug, Zilurgisertib-- quietly stalk endpoints. $INCY ti.e-up and Bluejay acquisition a plus: https://seekingalpha.com/article/4919805-mirm-this-liver-disease-juggernaut-just-broadened-its-portfolio

0 · Reply

BullsOnPrade Jul. 3 at 11:26 PM

$INCY it it to win-cy itit 👀

0 · Reply

peloswing Jul. 3 at 8:13 PM

Some large buys on September $INCY puts yesterday. $110 and $100 strikes 🔴

0 · Reply

Incyte price target raised to $136 from $124 at BofA

2026-07-14T09:40:11.000Z - 1 day ago

Incyte price target raised to $134 from $117 at Barclays

2026-07-13T12:55:09.000Z - 2 days ago

Hemab Therapeutics price target raised to $47 from $39 at Jefferies

COAG

2026-07-13T12:26:56.000Z - 2 days ago

Incyte price target raised to $112 from $94 at BMO Capital

2026-07-13T09:15:30.000Z - 2 days ago

Incyte announces safety, efficacy data from VGA039 study

Jul 13, 2026, 4:00 AM EDT - 2 days ago

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Jul 8, 2026, 8:00 AM EDT - 7 days ago

Incyte to Report Second Quarter Financial Results

2026-07-07T11:25:50.000Z - 8 days ago

Incyte price target raised to $99 from $95 at RBC Capital

2026-07-06T12:46:26.000Z - 9 days ago

Incyte completes acquisition of Vega Therapeutics

Jul 6, 2026, 8:39 AM EDT - 9 days ago

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Jul 3, 2026, 11:58 AM EDT - 12 days ago

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

2026-06-26T11:35:08.000Z - 19 days ago

Incyte announces positive CHMP opinion of Opzelura Cream

Jun 26, 2026, 7:30 AM EDT - 19 days ago

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

2026-06-26T10:35:53.000Z - 19 days ago

Incyte price target raised to $113 from $103 at UBS

2026-06-22T17:50:37.000Z - 22 days ago

Incyte price target raised to $105 from $103 at Truist

2026-06-22T08:35:45.000Z - 23 days ago

Incyte upgraded to Market Perform from Underperform at BMO Capital

2026-06-19T11:10:35.000Z - 26 days ago

Incyte Japan announces approval of Minjuvi combination for DLBCL

$Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)$

Jun 19, 2026, 2:00 AM EDT - 26 days ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

2026-06-14T21:20:07.000Z - 4 weeks ago

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

MIRM

2026-06-14T21:15:33.000Z - 4 weeks ago

Incyte announces clinical data from two Phase 2 studies of INCA033989

2026-06-14T21:10:35.000Z - 4 weeks ago

Incyte announces results from Phase 3 frontMIND trial of tafasitamab

Jun 14, 2026, 4:35 PM EDT - 4 weeks ago

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

MIRM

Jun 13, 2026, 11:15 AM EDT - 4 weeks ago

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Jun 13, 2026, 6:00 AM EDT - 4 weeks ago

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Jun 9, 2026, 8:40 AM EDT - 5 weeks ago

Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T18:55:10.000Z - 5 weeks ago

Incyte price target raised to $107 from $90 at Oppenheimer

2026-06-08T18:00:44.000Z - 5 weeks ago

Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal

COAG

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Incyte Transcript: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Incyte Press release: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Incyte Slides: M&A announcement

Jun 8, 2026, 7:34 AM EDT - 5 weeks ago

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Jun 8, 2026, 7:07 AM EDT - 5 weeks ago

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

Jun 8, 2026, 7:00 AM EDT - 5 weeks ago

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Jun 7, 2026, 6:11 AM EDT - 5 weeks ago

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

May 30, 2026, 8:02 AM EDT - 6 weeks ago

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

May 30, 2026, 8:00 AM EDT - 6 weeks ago

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 27, 2026, 8:00 AM EDT - 7 weeks ago

Incyte Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 7 weeks ago

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 12:10 PM EDT - 2 months ago

Inside Incyte's $120 Million AI For Drug Development Deal

May 20, 2026, 8:00 AM EDT - 2 months ago

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

May 19, 2026, 10:30 AM EDT - 2 months ago

Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 2 months ago

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

May 13, 2026, 4:40 PM EDT - 2 months ago

Incyte Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 9:30 AM EDT - 2 months ago

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

May 7, 2026, 8:50 AM EDT - 2 months ago

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

May 6, 2026, 4:30 PM EDT - 2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 5:28 PM EDT - 2 months ago

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Apr 29, 2026, 8:00 AM EDT - 2 months ago